You are here

Turning Point Therapeutics

Biopharma’s 5 Biggest M&A Deals of 2022

Biopharma’s 5 Biggest M&A Deals of 2022

BioSpace

Horizon Therapeutics

Global Blood Therapeutics

Bristol Myers Squibb

Turning Point Therapeutics

Flag link:

Bristol Myers completes Turning Point Acquisition

Bristol Myers completes Turning Point Acquisition

Pharmaceutical Business Review

Bristol Myers Squibb

Turning Point Therapeutics

Flag link:

Biopharma takeout spend ticks up

Biopharma takeout spend ticks up

EP Vantage

Bristol Myers Squibb

Turning Point Therapeutics

Sierra Oncology

Halozyme Therapeutics

Flag link:

Bristol Myers bets $4B on Turning Point and its targeted cancer drugs

Bristol Myers bets $4B on Turning Point and its targeted cancer drugs

BioPharma Dive

Bristol Myers Squibb

Turning Point Therapeutics

Flag link:

Turning Point looks to challenge Pfizer, Roche with new early data for lead lung cancer drug

Turning Point looks to challenge Pfizer, Roche with new early data for lead lung cancer drug

Endpoints

Turning Point Therapeutics

clinical trials

non-small cell lung cancer

Flag link:

Triple meeting – the point of turning to TPX-0022

Triple meeting – the point of turning to TPX-0022

EP Vantage

Turning Point Therapeutics

non-small cell lung cancer

Flag link:

Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?

Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?

Endpoints

Turning Point Therapeutics

non-small cell lung cancer

clinical trials

Flag link:

Important catalysts approach for smaller biotechs

Important catalysts approach for smaller biotechs

EP Vantage

Turning Point Therapeutics

Intra-Cellular Therapies

clinical trials

Flag link:

Biotech companies raise cash as coronavirus updates lift stocks

Biotech companies raise cash as coronavirus updates lift stocks

BioPharma Dive

Moderna Therapeutics

Turning Point Therapeutics

Krystal Biotech

Clovis Oncology

Flag link:

Turning Point Therapeutics Files for $296 Million Offering

Turning Point Therapeutics Files for $296 Million Offering

CP Wire

Turning Point Therapeutics

Flag link:

Turning Point Therapeutics Files for $296 Million Offering

Turning Point Therapeutics

Flag link:

Back to business for biotech flotations

Back to business for biotech flotations

EP Vantage

Turning Point Therapeutics

Stoke Therapeutics

Prevail Therapeutics

NGM Biopharmaceuticals

Akero Therapeutics

Milestone Pharmaceuticals

Morphic Therapeutics

Flag link:

3 takeaways from cancer's biggest conference

3 takeaways from cancer's biggest conference

Biopharma Dive

accelerated approvals

Turning Point Therapeutics

Flag link:

ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR

ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR

Fierce Biotech

clinical trials

Turning Point Therapeutics

non-small cell lung cancer

Flag link:

Turning Point sinks on ASCO update for repotrectinib

Turning Point sinks on ASCO update for repotrectinib

BioCentury

Turning Point Therapeutics

non-small cell lung cancer

Flag link:

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Yahoo/Benzinga

Wave Life Sciences

Sarepta Therapeutics

Intuitive Surgical

Turning Point Therapeutics

Flag link:

Turning Point Therapeutics Updates Its IPO Filing – Will Raise Up to $152 Million

Turning Point Therapeutics Updates Its IPO Filing – Will Raise Up to $152 Million

CP Wire

Turning Point Therapeutics

Flag link:

Turning Point Therapeutics Updates Its IPO Filing – Will Raise Up to $152 Million

Turning Point Therapeutics

Flag link:

Early Stage Oncology Biotech Files for $100 Million IPO

Early Stage Oncology Biotech Files for $100 Million IPO

CP Wire

Turning Point Therapeutics

Flag link:

Early Stage Oncology Biotech Files for $100 Million IPO

Turning Point Therapeutics

Flag link: